Yazar "Bozcuk, Hakan" seçeneğine göre listele

Listeleniyor 1 - 12 / 12
  • Küçük Resim
    Öğe
    Correlation of Serum Leptin Level and Waist-to-hip Ratio (WHR) With Overall Survival of Patients With Metastatic Breast Cancer (MBC) Treated With Aromatase Inhibitors (AIs).
    (Amer Soc Clinical Oncology, 2013) Artac, Mehmet; Bozcuk, Hakan; Kıyıcı, Aysel; Eren, Orhan Önder; Boruban, Melih Cem; Özdoğan, Mustafa
    Introduction Our objective was to determine whether serum leptin levels and obesity-related factors could affect outcome for metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs). Methods Sixty MBC patients treated with first line hormonal therapy were enrolled in this study. Results Median age was 51 years (range 28–75). Median leptin level was 19400 pg/ml (1970–91900) and estradiol level 29.6 pg/ml (4.0–181.9). Factors associated with overall survival in univariate analysis were age and waist-to-hip ratio (WHR), whereas only WHR retained significance in the multivariate analysis. However, no factor was associated with progression-free survival. However, WHR was found to be a significant prognostic marker only if the leptin level was C19400 pg/ml (HR = 0.38; 95% CI: 0.16–0.91). Conclusions This study suggests that serum leptin levels and WHR together may serve as potential prognostic markers in MBC patients treated with AIs.
  • Küçük Resim Yok
    Öğe
    The debate about maintenance is not over in small-cell lung cancer
    (AMER SOC CLINICAL ONCOLOGY, 2007) Artac, Mehmet; Bozcuk, Hakan
    [Abstract not Available]
  • Küçük Resim
    Öğe
    Gene Methylation of SFRP2, P16, DAPKI, HIC1, and MGMT and KRAS Mutations in Sporadic Colorectal Cancer
    (Elsevier Science Inc, 2010) Pehlivan, Sacide; Artaç, Mehmet; Sever, Tuğçe; Bozcuk, Hakan; Kılınçarslan, Can; Pehlivan, Mustafa
    The aim of this study was to investigate the methylation of the SFRP2, P16, DAPK1, HIC1, and MGMT genes, as well as the mutation of amino acid codons 12 and 13 of the KRAS gene in normal and tumor tissue DNA of patients diagnosed with sporadic colorectal cancer (SCRC). The methylation of gene regions and the KRAS mutations of normal (N) and tumor tissue (T) DNA obtained from 17 patients diagnosed with SCRC and 20 healthy controls were investigated using the polymerase chain reaction and reverse-hybridization methods. There was an Asp mutation in four patients, an Asp and Ser mutations in one patient in codon 12 of the KRAS gene, and an Asp mutation in codon 13 in eight patients. Overall promoter methylation (OPM) in the SFRP2 gene was observed in one N and four T, whereas partial promoter methylation (PPM) was observed in two N and five T. OPM in the P16 gene was present in one T. In the DAPK1 gene, OPM existed in seven T and five N, while PPM was present in two N. In the HIC1 gene, OPM was demonstrated in three T, while PPM was noted in two N; however, no methylation existed in N. In the MGMT gene, OPM occurred in five T and two N, and PPM was present in one T. KRAS mutations in Turkish patients with SCRC are similar to those of other population groups. Methylations in the genes, which underwent methylation analysis, were higher in Tin comparison with N, and it has been suggested that significant results would be obtained by making a study with a larger population.
  • Küçük Resim Yok
    Öğe
    THE IMPACT OF LEPTIN AND ESTRADIOL LEVELS ON CLINICAL OUTCOMES IN METASTATIC BREAST CANCER (MBC) PATIENTS TREATED WITH AROMATASE INHIBITORS (AIS)
    (OXFORD UNIV PRESS, 2008) Artaç, Mehmet; Samur, Mustafa; Kıyıcı, Aysel; Afacan, Berna; Özdoğan, Mustafa; Bozcuk, Hakan
    [Abstract not Available]
  • Küçük Resim Yok
    Öğe
    The impact of waist-to-hip ratio (WHR) on survival in metastatic breast cancer patients treated with aromatase inhibitors (AIs)
    (AMER SOC CLINICAL ONCOLOGY, 2007) Artaç, Mehmet; Samur, Mustafa; Bozcuk, Hakan; Afacan, Berna; Özdoğan, Mustafa
    [Abstract not Available]
  • Küçük Resim Yok
    Öğe
    The impact of waist-to-hip ratio on clinical outcomes in metastatic breast cancer patients treated with aromatase inhibitors
    (Churchill Livingstone, 2008) Artaç, Mehmet; Bozcuk, Hakan; Afacan, Berna; Özdoğan, Mustafa; Samur, Mustafa
    We aimed to identify whether abdominal fat distribution could affect the outcome in metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs) or not. A total of 42 MBC patients treated with first line hormonal therapy were enrolled in this study. Factors associated with overall survival in the univariate analysis were age, c-erb-B2 expression intensity (+++ versus others by immunohistochemistry), and WHR, whereas only WHR retained significance in the multivariate analysis. Median overall survival figures were 472 days versus unreached for patients with a WHR of <0.92 and ?0.92 (Log rank statistic = 9.76, P = 0.002). Similarly, the corresponding progression free survival figures for patients with a WHR of <0.92 and ?0.92 were 423 versus 1004 days (Log rank statistic = 6.37, P = 0.012). This study suggests that WHR may serve as a potential predictive marker in MBC patients treated with AIs. © 2008 Elsevier Ltd. All rights reserved.
  • Küçük Resim Yok
    Öğe
    METHYLATION OF SFRP2, P16, DAPK1, HIC1 AND MGMT GENES AND RELATING K-Ras GENE (CODONS 12-13) MUTATIONS WITH COLORECTAL CANCERS
    (JOHN WILEY & SONS INC, 2009) Pehlivan, Sacide; Artac, Mehmet; Kilicarslan, Can; Bozcuk, Hakan; Sever, Tugce; Pehlivan, Mustafa
    [Abstract not Available]
  • Küçük Resim Yok
    Öğe
    Metronomic oral chemotherapy with old agents in patients with heavily treated metastatic breast cancer
    (MEDKNOW PUBLICATIONS & MEDIA PVT LTD, 2015) Mutlu, Hasan; Musri, Fatma Yalcin; Artac, Mehmet; Kargi, Aysegul; Ozdogan, Mustafa; Bozcuk, Hakan
    Background: We aimed to assess the efficacy of a metronomic regimen with cyclophosphamide and etoposide in heavily treated patients with metastatic breast cancer (MBC). Materials and Methods: A total of 77 patients with MBC used continuous oral cyclophosphamide 50 mg/day and oral etoposide given as 2 x 50 mg/day for 2 days per week, were analyzed retrospectively from Akdeniz University and Selcuk University. The patients with MBC are predominantly refractory to antracyclines, taxanes, and antimetabolites. Results: The patients were treated and followed between May 2005 and June 2014. The median progression-free and overall survival (PFS and OS) were 7.03 (5.06-8.99) and 32.5 (22.5-42.4) months, respectively. No prognostic factor was found for OS. Conclusions: Metronomic treatment regimen with cyclophosphamide and etoposide is a novel and effective strategy in heavily pretreated MBC patients. This regimen can be used in early or late steps as independently from prognostic factors. Moreover, it has very low toxicity and is cheap. Impressive survival data and low cost may make this regimen a highly preferable option.
  • Küçük Resim Yok
    Öğe
    The predictors of information needs and different views of patients and relatives on disclosure and treatment participation: A multicentric survey study
    (AMER SOC CLINICAL ONCOLOGY, 2009) Özdoğan, Mustafa; Bozcuk, Hakan; Er, O.; Abalı, Hüseyin; Coşkun, Hasan Şenol; Zengin, N; Artaç, Mehmet; Savaş, Burhan
    [Abstract not Available]
  • Küçük Resim Yok
    Öğe
    Serum leptin level and waist-to-hip ratio (WHR) predict the overall survival of metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs)
    (SPRINGER JAPAN KK, 2013) Artac, Mehmet; Bozcuk, Hakan; Kiyici, Aysel; Eren, Orhan Onder; Boruban, Melih Cem; Ozdogan, Mustafa
    Our objective was to determine whether serum leptin levels and obesity-related factors could affect outcome for metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs). Sixty MBC patients treated with first line hormonal therapy were enrolled in this study. Median age was 51 years (range 28-75). Median leptin level was 19400 pg/ml (1970-91900) and estradiol level 29.6 pg/ml (4.0-181.9). Factors associated with overall survival in univariate analysis were age and waist-to-hip ratio (WHR), whereas only WHR retained significance in the multivariate analysis. However, no factor was associated with progression-free survival. However, WHR was found to be a significant prognostic marker only if the leptin level was a parts per thousand yen19400 pg/ml (HR = 0.38; 95% CI: 0.16-0.91). This study suggests that serum leptin levels and WHR together may serve as potential prognostic markers in MBC patients treated with AIs.
  • Küçük Resim Yok
    Öğe
    STRATEGIES FOR INDEPTH INVOLVEMENT OF NATIONAL ACCREDIATIALING PROGRAMS IN CANCER CARE THE TURKISH EXPERIENCE
    (WILEY-BLACKWELL, 2014) Turhal, Serdar; Saip, Pinar; Sahin, Berksoy; Bozcuk, Hakan; Coskun, Senol; Karabulut, Bulent; Artac, Mehmet
    [Abstract not Available]
  • Küçük Resim Yok
    Öğe
    The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens
    (SPRINGER, 2010) Artaç, Mehmet; Bozcuk, Hakan; Pehlivan, Sacide; Akcan, Songül; Pehlivan, Mustafa; Sever, Tuğçe; Özdoğan, Mustafa
    Previous studies have suggested that DNA repair enzyme polymorphisms may bear prognostic value in metastatic colorectal carcinoma (MCRC). We prospectively treated 43 MCRC patients with irinotecan-based regimens (XELIRI or IFL). Allelic variants of the XRCC1 gene at codon 399 and XPD gene at codon 751 were analyzed in lymphocyte DNA by PCR-RFLP. Clinical outcome variables: overall survival (OAS), progression-free survival (PFS) and the occurrence of grade 3 or 4 hematological and gastrointestinal (GIS) toxicities were evaluated. In the univariate analysis for OAS (n = 43) only XPD and XRCC1 polymorphisms were significant (P = 0.05 and P = 0.04, respectively). After adjustment for performance status (ECOG = 0, 1 vs. 2) and disease extent (single vs. multiple metastatic site), XRCC1 genotype and performance status retained significance (HR = 2.85, P = 0.04, and HR = 3.19, P = 0.02, respectively). Gln/Gln genotype was associated with the greatest risk of death. Type of presentation (metastatic vs. local disease at first presentation) was the only significant predictor of PFS in the univariate analysis (n = 40, P = 0.003). After adjustment for performance status and disease extent, type of presentation retained its significance (HR = 4.35, P = 0.003). None of the toxicities was associated with these genotypes. XRCC1 genotype independently predicted overall survival in metastatic colorectal carcinoma patients treated with irinotecan-based chemotherapy.